Nutriband Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Gareth Sheridan
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 121 South Orange Avenue Orlando FL United States of America 32801
- IPO Date
- Oct 1, 2021
- CIK
- 0001676047
- Website
- nutriband.com
- Similar Companies
- Business
- Nutriband Inc. (Ticker: NTRBW) develops and commercializes transdermal drug delivery patch technologies for pharmaceutical applications, including branded prescription products such as NourishGel for nausea and vomiting prevention and AVERSA for opioid overdose reversal; the company also offers its proprietary AVERSA technology platform featuring the world's first antagonist-releasing skin-adherent patch designed to block oral opioid abuse while enabling therapeutic use. Founded in 2015 and headquartered in Orlando, Florida, Nutriband operates primarily in the United States with a focus on the pharmaceutical and healthcare sectors, targeting patients, healthcare providers, and pharmaceutical partners seeking abuse-deterrent and controlled-release delivery solutions. In recent developments, Nutriband completed a merger with Kowa Pharmaceuticals America in late 2023 to expand its commercial infrastructure and accelerate product launches; the company secured a $17.5 million funding round in early 2025 to support regulatory submissions and manufacturing scale-up for AVERSA; and it announced a strategic partnership with a leading contract manufacturer in mid-2025 to enhance production capacity for its NourishGel and AVERSA pipelines amid growing demand for abuse-deterrent opioid formulations.
Company News
Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274
Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis
Nutriband Inc. (NASDAQ:NTRBW) Short Interest Update
Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica
Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
Nutriband CEO Publishes Letter to Shareholders
Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
Nutriband (NASDAQ:NTRBW) Trading 0.7% Higher – Should You Buy?
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
Nutriband (NASDAQ:NTRBW) Shares Down 5% – What’s Next?
Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference